SCHEMBL17015131

SCHEMBL17015131

CCc1ccc(Cl)c(SC(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.41
SIGMAR1 Q99720 5/20 0.35
TRPA1 O75762 1/20 0.34
PTPRZ1 P23471 2/20 0.34
PTPN1 P18031 1/20 0.34
PYCR1 P32322 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
IDO1 P14902 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
PDK2 Q15119 1/20 0.33
MME P08473 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015093 0.83 KCNN4 (0.40) KCNN4PTPRZ1PTPN1PYCR1FFAR4
SCHEMBL16388007 0.82 KCNN4 (0.41) KCNN4PTPRZ1PTPN1PYCR1FFAR4
SCHEMBL16200087 0.77 TRPA1 (0.39) SIGMAR1TRPA1IDO1CYP3A4CYP2C9
SCHEMBL16976330 0.76 PDK1 (0.37) KCNN4CYP2C9CYP1A2CYP2A6PDK2
SCHEMBL17378569 0.75 TP53 (0.42) KCNN4CYP3A4CYP2C9CYP1A2PDK2
SCHEMBL6117621 0.73 PTPN1 (0.31) TRPA1PTPRZ1PTPN1CYP1A2CYP2A6
SCHEMBL900914 0.72
SCHEMBL6116327 0.72 PTPN1 (0.30) TRPA1PTPRZ1PTPN1PDK2
SCHEMBL16555673 0.72 PDE2A (0.41) MEN1ALDH1A1MAPTKMT2A
SCHEMBL257060 0.72 IDO1 (0.61) PYCR1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS INTERVET INC. (US) 2017-07-13 US disclosed
US-9533999-B2 Fused thiazin-3-ones as KCA3.1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-01-03 US disclosed
US-20150232484-A1 FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-08-20 US disclosed
US-20150232484-A1 FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS MPO, DHODH, DHX35 KCNN4 2587/4885SIGMAR1 4211/4885TRPA1 595/4885
US-20150232484-A1 FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS KCNA3, KCNK3, KCNN3 KCNN4 76/4885SIGMAR1 2193/4885TRPA1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.